ES2989511T3 - Composición para la estimulación ovárica controlada - Google Patents

Composición para la estimulación ovárica controlada Download PDF

Info

Publication number
ES2989511T3
ES2989511T3 ES21196378T ES21196378T ES2989511T3 ES 2989511 T3 ES2989511 T3 ES 2989511T3 ES 21196378 T ES21196378 T ES 21196378T ES 21196378 T ES21196378 T ES 21196378T ES 2989511 T3 ES2989511 T3 ES 2989511T3
Authority
ES
Spain
Prior art keywords
amh
patient
fsh
dose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21196378T
Other languages
English (en)
Spanish (es)
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of ES2989511T3 publication Critical patent/ES2989511T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES21196378T 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada Active ES2989511T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01

Publications (1)

Publication Number Publication Date
ES2989511T3 true ES2989511T3 (es) 2024-11-26

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21196378T Active ES2989511T3 (es) 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada
ES18768795T Active ES2904787T3 (es) 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18768795T Active ES2904787T3 (es) 2017-09-01 2018-08-31 Composición para la estimulación ovárica controlada

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP4427806A3 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20200045543A (enExample)
CN (2) CN111050787A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3973982T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2989511T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20211802T1 (enExample)
HU (2) HUE068024T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3675894T (enExample)
MA (2) MA56224B1 (enExample)
MD (2) MD3973982T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3675894T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS62810B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3973982T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418107A (zh) * 2000-01-27 2003-05-14 应用研究系统Ars股份公司 用于治疗不孕症的卵泡刺激激素(fsh)的应用
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (en) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2526111A2 (en) * 2010-01-21 2012-11-28 Ramot at Tel Aviv University, Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
HRP20150968T4 (hr) 2010-09-29 2023-11-10 Ferring B.V. Pripravak za uporabu za liječenje neplodnosti
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
US20170035854A1 (en) * 2014-04-18 2017-02-09 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
RU2723098C2 (ru) 2015-02-26 2020-06-08 Ферринг Б.В. Способы лечения бесплодия
ES2784625T3 (es) 2015-04-17 2020-09-29 Ferring Bv FSH para el tratamiento de la infertilidad
MX389908B (es) 2015-04-24 2025-03-20 Ferring Bv Metodo de produccion de gonadotrofina.
EP3313859B1 (en) 2015-06-26 2019-11-20 Ferring BV Methods of purification and/or viral inactivation
EP3787667B1 (en) 2018-04-30 2025-03-26 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
KR20250078595A (ko) 2025-06-02
IL272763B2 (en) 2024-02-01
JP6856819B2 (ja) 2021-04-14
EP3973982A1 (en) 2022-03-30
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
PT3675894T (pt) 2022-01-25
JP7373479B2 (ja) 2023-11-02
HRP20241171T1 (hr) 2024-11-22
AR112541A1 (es) 2019-11-06
JP2021046398A (ja) 2021-03-25
SI3675894T1 (sl) 2022-01-31
US11744879B2 (en) 2023-09-05
JOP20200034A1 (ar) 2020-02-13
PT3973982T (pt) 2024-09-16
BR112020003379A2 (pt) 2020-08-25
MA56224A (fr) 2022-04-20
MA50034B1 (fr) 2022-02-28
UA126869C2 (uk) 2023-02-15
TW201919687A (zh) 2019-06-01
EP3675894A1 (en) 2020-07-08
SG11202003840QA (en) 2020-05-28
CL2020000482A1 (es) 2020-06-26
AU2018326556B2 (en) 2024-09-26
MY200791A (en) 2024-01-16
HUE056726T2 (hu) 2022-03-28
MX2020002235A (es) 2020-07-20
CN111050787A (zh) 2020-04-21
FI3973982T3 (fi) 2024-09-23
ES2904787T3 (es) 2022-04-06
MD3675894T2 (ro) 2022-03-31
EP3675894B1 (en) 2021-11-03
LT3973982T (lt) 2024-09-10
KR20200045543A (ko) 2020-05-04
US20200197493A1 (en) 2020-06-25
PH12020500404A1 (en) 2021-03-01
SI3973982T1 (sl) 2024-10-30
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
US20240024424A1 (en) 2024-01-25
HRP20211802T1 (hr) 2022-03-04
DK3973982T3 (da) 2024-09-23
IL272763A (en) 2020-04-30
HUE068024T2 (hu) 2024-12-28
MA56224B1 (fr) 2024-09-30
EP3973982B1 (en) 2024-07-31
PL3973982T3 (pl) 2024-11-04
JP2020528071A (ja) 2020-09-17
MD3973982T2 (ro) 2024-11-30
CA3073624A1 (en) 2019-03-07
EP4427806A3 (en) 2024-10-09
MX2024009224A (es) 2024-08-06
EP4427806A2 (en) 2024-09-11
DK3675894T3 (da) 2022-01-24
AU2018326556A1 (en) 2020-03-05
RS65945B1 (sr) 2024-10-31
WO2019043143A1 (en) 2019-03-07
TWI749255B (zh) 2021-12-11
CN120617484A (zh) 2025-09-12
RS62810B1 (sr) 2022-02-28
MA50034A (fr) 2021-05-12

Similar Documents

Publication Publication Date Title
ES3029733T3 (en) Composition for controlled ovarian stimulation
ES2879838T3 (es) Composición que comprende FSH para el tratamiento de la esterilidad
US20240024424A1 (en) Composition for controlled ovarian stimulation
EP3866833B1 (en) Compositions comprising a recombinant fsh for the treatment of infertility
HK40115814A (en) Composition for controlled ovarian stimulation
HK40066975B (en) Composition for controlled ovarian stimulation
HK40066975A (en) Composition for controlled ovarian stimulation
HK40021791B (en) Composition for controlled ovarian stimulation
EA046202B1 (ru) Композиция для контролируемой стимуляции яичников
HK40055068B (en) Compositions comprising a recombinant fsh for the treatment of infertility
HK40055068A (en) Compositions comprising a recombinant fsh for the treatment of infertility